StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $0.34 | $0.33 | -2.54% | 1.2M |
| 05-11 | $0.34 | $0.32 | -3.34% | 0.9M |
| 05-12 | $0.31 | $0.31 | -0.06% | 1.1M |
| 05-13 | $0.30 | $0.30 | -0.67% | 0.8M |
| 05-14 | $0.29 | $0.28 | -3.02% | 1.0M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2018 2018-03-31 | Q1 2016 2016-03-31 | Q4 2015 2015-12-31 | Q4 2013 2013-12-31 |
|---|---|---|---|---|
Revenue | $0.00 | $42.52K | $42.52K | $32.77K |
Operating Income | $-5.15M | $-1.45M | $-936.34K | $-1.74M |
Net Income | $-4.26M | $-979.64K | $-772.08K | $-2.15M |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $144.26M | $980.51K | $1.34M | $450.47K |
Total Liabilities | $906.07K | $1.04M | $893.91K | $2.13M |
Cash & Equivalents | $17.02M | $151.22K | $531.26K | $18.79K |
Free Cash Flow OCF − CapEx | $-2.76M | Not available | Not available | Not available |
Shares Outstanding | 36.16M | 9.53M | 9.53M | 6.00M |
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
No sell-side coverage available for LNAI.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.